Amarin Corporation plc (AMRN) Cash Flow Statement

The gap between net income and operating cash flow is stark: in 2026Q2, a net loss of $7.7M produced $40.3M of operating cash flow, a swing of $48M, almost entirely from a $19.2M working capital benefit. This pattern repeats across quarters, with working capital changes often exceeding net income in magnitude, indicating that cash generation is not a function of underlying profitability but of timing and inventory/payable management. Investors should monitor whether these working capital swings are sustainable or represent one-time liquidations.

The FCF trajectory is highly erratic, with positive quarters in 2025Q2, 2025Q4, and 2026Q2, but negative in others, and the latest quarter's 95.4% FCF margin is an artifact of low revenue and a large working capital release. Over the trailing four quarters, FCF totals roughly $49M, but this is not a reliable indicator of sustainable cash generation given the revenue decline and negative net income. The company appears to be managing cash through working capital rather than operational profitability, which may not be repeatable.

The working capital line is the primary driver of operating cash flow variability, with positive contributions in four of the last five quarters, but negative in 2025Q3 and 2024Q2. This pattern suggests that Amarin may be reducing inventory or accelerating collections, but the inconsistency across quarters raises questions about the sustainability of these cash inflows. Given the revenue decline, the working capital benefits may be a result of shrinking the business rather than efficient cycle management, which could reverse as the company stabilizes.

Amarin's capital expenditures are minimal, averaging less than $1M per quarter, which is consistent with a commercial-stage biotech that outsources manufacturing. This low capex means that free cash flow closely tracks operating cash flow, but it also implies that the company is not investing in growth infrastructure. The lack of capex may limit future expansion, but it also reduces the cash burn, which is critical given the revenue decline.

With no dividends and minimal buybacks, Amarin is not returning capital to shareholders, which is typical for a company with negative net income and uncertain cash flows. The $59K buyback in 2026Q2 is immaterial, and the company appears to be preserving cash to weather the revenue decline. This conservative deployment suggests that management is prioritizing liquidity over shareholder returns, which may be prudent given the operational challenges.